Discussion to: Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer
- PMID: 38340115
- DOI: 10.1016/j.jtcvs.2024.01.009
Discussion to: Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer
Conflict of interest statement
Conflict of Interest Statement Dr Bott has received speaking honorarium and consulting fees from Intuitive Surgical, consulting fees from AstraZeneca Pharmaceuticals, and research support from Obsidian Therapeutics. All other authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.
Comment on
-
Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer.J Thorac Cardiovasc Surg. 2024 Apr;167(4):1444-1453.e4. doi: 10.1016/j.jtcvs.2023.09.073. Epub 2023 Oct 8. J Thorac Cardiovasc Surg. 2024. PMID: 37816395
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical